JFK University Medical Center Offers PSMA PET Imaging Test to Aid in Diagnosis of Prostate Cancer

What You Need to Know

JFK University Medical Center now offers PYLARIFY® (piflufolastat F 18) injection, a prostate cancer imaging test.

The injection is given to a patient through a vein in the arm. That injection binds to prostate cancer cells sending a radio signal which, during a PET scan, shows where the drug is gathering to indicate where the cancer is. A three dimensional picture of the inside of the body, enables doctors to see lymph nodes, bone, and soft tissue metastasis to determine the presence or absence of recurrent and/or metastatic prostate cancer. 

PYLARIFY is indicated for patients with suspected prostate cancer metastasis who are potentially curable via surgery or other therapy. Patients are considered for PSMA if a blood test shows high levels of PSA. If there is a high PSA level then a doctor may order the PSMA test. It is also indicated for patients with suspected prostate cancer recurrence based on elevated serum prostate-specific antigen (PSA) levels.